Selective amylin receptor agonist

Eloralintide

Efficacy-estimand weight reduction was approximately 20% in the 9 mg group versus 0.4% placebo.

Evidence Maturity · M3 — Clinical Investigational for obesity

Evidence reviewed: September 19, 2026Source-labeled

Evidence in context

Nausea and fatigue varied by regimen. The recruiting ENLIGHTEN-2 phase 3 trial is a separate program, not phase 3 efficacy proof.

Study details

Doses studied — not a dosing recommendation. Regimens belong to the named study, formulation and population.

Phase 2 randomized obesity trial

Population: 263 adults without type 2 diabetes.
Doses and administration studied: Subcutaneous 1, 3, 6 or 9 mg once weekly; separate groups escalated from 6 to 9 mg or 3 to 9 mg.
Duration: 48 weeks
Reported finding / status: Efficacy-estimand weight reduction was approximately 20% in the 9 mg group versus 0.4% placebo.
Interpretation and limitations: Nausea and fatigue varied by regimen. The recruiting ENLIGHTEN-2 phase 3 trial is a separate program, not phase 3 efficacy proof.

Source tier B · Read the original study or record

Outcome Evidence Strength

Weight change3/5

Fat-mass change0/5

Lean-mass change0/5

Strength / function benefit0/5

Weight: published phase 2 RCT. Direct lean preservation or functional advantage is not established by this report.

Editorial evidence ratings for the cited outcomes, not effect size or treatment recommendations. A lean-mass score may describe loss. 0 means not established in the reviewed evidence, not proof of no effect. Read the rubric.

Pipeline status

ENLIGHTEN-2 is a recruiting Phase 3 study in adults with obesity/overweight and type 2 diabetes. Registration establishes study status, not results.

ENLIGHTEN-2 registry